Immune-based combination therapy for esophageal cancer

Immune-based combination therapy for esophageal cancer

Esophageal cancer (EC) is an aggressive malignancy raising a healthcare concern worldwide. Standard treatment options include surgical resection, chemotherapy, radiation therapy, and targeted molecular therapy. The five-year survival rate for all stages of EC is approximately 20%, ranging from 5% to...

Full description

Bibliographic Details
Main Authors:	Huiling Wang, Yufei Xu, Fengli Zuo, Junzhi Liu, Jiqiao Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Immunology
Subjects:	esophageal cancer immunotherapy chemotherapy radiotherapy combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1020290/full

Similar Items

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
by: Yiyi Yan, et al.
Published: (2018-07-01)

Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new
by: Clare Y. Slaney, et al.
Published: (2023-01-01)

Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma
by: Hiroshi Saeki, et al.
Published: (2020-09-01)

Nanodrugs systems for therapy and diagnosis of esophageal cancer
by: Lihan Zhang, et al.
Published: (2023-07-01)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
by: Xiao-Han Zhao, et al.
Published: (2023-09-01)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
by: Qing Li, et al.
Published: (2022-12-01)

Novel Combination Therapies for the Treatment of Bladder Cancer
by: Mei Peng, et al.
Published: (2021-01-01)

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma
by: Alisa Ageenko, et al.
Published: (2024-02-01)

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
by: Lin Zhu, et al.
Published: (2024-06-01)

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study
by: Evelyn Herrmann, et al.
Published: (2017-06-01)

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
by: Runkai Huang, et al.
Published: (2022-04-01)

Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
by: Maohui Chen, et al.
Published: (2023-08-01)

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma
by: Renxian Xie, et al.
Published: (2024-01-01)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
by: Xinyi Xiao, et al.
Published: (2022-08-01)

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer
by: Sicong Hou, et al.
Published: (2021-10-01)

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma
by: Zhen Wang, et al.
Published: (2022-06-01)

Endoscopic esophageal stenting in combination with chemoradiation therapy: A review
by: Aleksej I. Ivanov, et al.
Published: (2021-12-01)

Proton Beam Therapy for Esophageal Cancer
by: Jea Giezl N. Solidum, et al.
Published: (2022-08-01)

The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients
by: Meng Yuan, et al.
Published: (2021-03-01)

History and current situation of neoadjuvant treatment for locally advanced esophageal cancer
by: Junyi Li, et al.
Published: (2021-09-01)

Esofagectomia de resgate após quimiorradioterapia radical exclusiva: resultados do departamento de cirurgia abdôminopélvica do Instituto Nacional de Câncer
by: Carlos Eduardo Pinto, et al.

Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study
by: Saber Amin, et al.
Published: (2024-01-01)

Role of a multidisciplinary team in administering radiotherapy for esophageal cancer
by: Shengguang Zhao, et al.
Published: (2020-10-01)

Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment
by: Siyuan Luan, et al.
Published: (2021-03-01)

Progress on TTFields combined with other therapies for glioblastoma treatment: A narrative review
by: Yong Cao, et al.
Published: (2022-01-01)

Clinical results of proton beam therapy for twenty older patients with esophageal cancer
by: Ono Takashi, et al.
Published: (2015-12-01)

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis
by: Koichi Kitagawa, et al.
Published: (2021-11-01)

Nanoparticle-Based Combination Therapy for Melanoma
by: Hongbo Chen, et al.
Published: (2022-06-01)

Editorial: Radiotherapy for esophageal cancer: Molecular mechanism and novel targets to improve radiosensitivity
by: Yanqing Liu, et al.
Published: (2023-04-01)

Evaluation of Cytogenetic Alterations in Peripheral Blood Lymphocytes of Esophageal Cancer Patients Treated with Radiotherapy or Chemoradiotherapy using Cytokinesis-Blocked Micronucleus Assay
by: Soraya Emamgholizadeh Minaei, et al.
Published: (2016-02-01)

Embryonic esophageal rhabdomyosarcoma in an adult male: A case report and literature review
by: Xiaoman Zhang, et al.
Published: (2022-09-01)

Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
by: Satoshi Komoto, et al.
Published: (2023-05-01)

A Randomized Clinical Study on Combination of Concurrent Chemo-Radiotherapy and Thalidomide for Middle-Late Esophageal Cancer
by: Gui-zhi LI, et al.
Published: (2010-04-01)

Gut Microbiota Shapes the Efficiency of Cancer Therapy
by: Weidong Ma, et al.
Published: (2019-06-01)

Lymph Node Status after Neoadjuvant Chemoradiation Therapy for Esophageal Cancer according to Radiation Field Coverage
by: Sang Yoon Kim, et al.
Published: (2019-10-01)

Mechanisms of esophageal cancer metastasis and treatment progress
by: Yusheng Wang, et al.
Published: (2023-06-01)

Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy
by: Blanchard Pierre, et al.
Published: (2012-03-01)

Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
by: Shayan Khalafi, et al.
Published: (2020-10-01)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
by: Ying Li, et al.
Published: (2022-12-01)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
by: Tom van den Ende, et al.
Published: (2023-12-01)